

James M Ford

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3599277/james-m-ford-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

184
papers

11,316
citations

59
h-index

104
g-index

208
ext. papers

13,168
ext. citations

6.7
avg, IF

5.99
L-index

#	Paper	IF	Citations
184	Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 3764-73	12.9	438
183	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. <i>Journal of Medical Genetics</i> , 2015 , 52, 361-74	5.8	385
182	p53-mediated DNA repair responses to UV radiation: studies of mouse cells lacking p53, p21, and/or gadd45 genes. <i>Molecular and Cellular Biology</i> , 2000 , 20, 3705-14	4.8	369
181	Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2001-9	2.2	363
180	American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3660-7	2.2	360
179	Clinical interpretation and implications of whole-genome sequencing. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 1035-45	27.4	333
178	Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 2360-72	27.4	324
177	Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. <i>Cancer</i> , 2009 , 115, 665-72	6.4	291
176	Xeroderma pigmentosum p48 gene enhances global genomic repair and suppresses UV-induced mutagenesis. <i>Molecular Cell</i> , 2000 , 5, 737-44	17.6	275
175	Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 63, 320-3	4	267
174	Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. <i>Journal of Biological Chemistry</i> , 1997 , 272, 28073-80	5.4	259
173	Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 72, 678-86	4	257
172	p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 12985-90	11.5	251
171	Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. <i>Annals of Internal Medicine</i> , 2011 , 155, 69-79	8	248
170	Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. <i>JAMA Oncology</i> , 2015 , 1, 943-51	13.4	226
169	Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. <i>Cancer Research</i> , 2010 , 70, 512-9	10.1	201
168	BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. <i>Nature Genetics</i> , 2002 , 32, 180-4	36.3	195

167	In vivo recruitment of XPC to UV-induced cyclobutane pyrimidine dimers by the DDB2 gene product. <i>Journal of Biological Chemistry</i> , 2003 , 278, 46906-10	5.4	192
166	HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 19482-7	11.5	189
165	Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 81, 181-8	4	188
164	Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. <i>Clinical Cancer Research</i> , 2005 , 11, 5401-9	12.9	168
163	Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1895-901	2.2	166
162	American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. <i>Journal of Clinical Oncology</i> , 2014 , 32, 833-40	2.2	164
161	Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. <i>PLoS ONE</i> , 2013 , 8, e54014	3.7	148
160	NCCN clinical practice guidelines in oncology. Colorectal cancer screening. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010 , 8, 8-61	7.3	145
159	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. <i>Cell</i> , 2020 , 181, 236-249	56.2	140
158	A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients. <i>Journal of Molecular Diagnostics</i> , 2015 , 17, 533-44	5.1	133
157	CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. <i>Annals of Surgery</i> , 2007 , 245, 873-9	7.8	133
156	p53 and regulation of DNA damage recognition during nucleotide excision repair. <i>DNA Repair</i> , 2003 , 2, 947-54	4.3	133
155	Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. <i>Cancer Research</i> , 2010 , 70, 7970-80	10.1	128
154	Long-read genome sequencing identifies causal structural variation in a Mendelian disease. <i>Genetics in Medicine</i> , 2018 , 20, 159-163	8.1	127
153	Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 1125-30	4.4	120
152	Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 4702-10	12.9	120
151	Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. <i>Cancer Research</i> , 2009 , 69, 3589-96	10.1	114
150	Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. <i>American Journal of Surgical Pathology</i> , 2008 , 32, 799-809	6.7	112

149	18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 77, 1420-5	4	101
148	HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2012 , 20, 13-24	1.9	97
147	Functional characterization of global genomic DNA repair and its implications for cancer. <i>Mutation Research - Reviews in Mutation Research</i> , 2003 , 544, 107-14	7	95
146	Hereditary diffuse gastric cancer: updated clinical practice guidelines. <i>Lancet Oncology</i> , 2020 , 21, e386-e397	21.7	95
145	Second primary breast cancer occurrence according to hormone receptor status. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 1058-65	9.7	90
144	Regulation of DNA damage recognition and nucleotide excision repair: another role for p53. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2005 , 577, 195-202	3.3	86
143	Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer. <i>Genome Biology</i> , 2014 , 15, 428	18.3	85
142	Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. <i>Molecular Pharmacology</i> , 2007 , 71, 1233-40	4.3	85
141	Opposing effects of the UV lesion repair protein XPA and UV bypass polymerase eta on ATR checkpoint signaling. <i>EMBO Journal</i> , 2006 , 25, 2605-14	13	84
140	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 1465-1475	7.3	81
139	The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. <i>Npj Breast Cancer</i> , 2017 , 3, 22	7.8	78
138	NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 939-949	7.3	78
137	Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. <i>American Journal of Surgical Pathology</i> , 2008 , 32, 1029-37	6.7	78
136	Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers. <i>Cancer Discovery</i> , 2015 , 5, 488-505	24.4	76
135	Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis. <i>PLoS ONE</i> , 2012 , 7, e43994	3.7	74
134	The DDB2 nucleotide excision repair gene product p48 enhances global genomic repair in p53 deficient human fibroblasts. <i>DNA Repair</i> , 2003 , 2, 819-26	4.3	74
133	A prospective study of total gastrectomy for CDH1-positive hereditary diffuse gastric cancer. <i>Annals of Surgical Oncology</i> , 2011 , 18, 2594-8	3.1	73
132	Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. <i>Genetics in Medicine</i> , 2018 , 20, 234-239	8.1	72

131	Longer relative telomere length in blood from women with sporadic and familial breast cancer compared with healthy controls. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 605-13	4	71
130	Hereditary diffuse gastric cancer: implications of genetic testing for screening and prophylactic surgery. <i>Cancer</i> , 2008 , 113, 1850-6	6.4	65
129	p53 responsive nucleotide excision repair gene products p48 and XPC, but not p53, localize to sites of UV-irradiation-induced DNA damage, in vivo. <i>Carcinogenesis</i> , 2003 , 24, 843-50	4.6	62
128	Interferon-beta represses cancer stem cell properties in triple-negative breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 13792-13797	11.5	61
127	Colorectal Cancer Screening, Version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 959-68; quiz 968	7.3	61
126	Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. <i>Journal of Medical Genetics</i> , 2016 , 53, 15-23	5.8	57
125	A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs. <i>Journal of Oncology Practice</i> , 2017 , 13, e108-e119	3.1	57
124	Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 625-630	4.4	55
123	Genetic testing by cancer site: stomach. <i>Cancer Journal (Sudbury, Mass)</i> , 2012 , 18, 355-63	2.2	55
122	Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. <i>Familial Cancer</i> , 2008 , 7, 179-86	3	54
121	Multigene Panel Testing in Oncology Practice: How Should We Respond?. <i>JAMA Oncology</i> , 2015 , 1, 277-81	3.4	53
120	The p53-regulated cyclin-dependent kinase inhibitor, p21 (cip1, waf1, sdi1), is not required for global genomic and transcription-coupled nucleotide excision repair of UV-induced DNA photoproducts. <i>Journal of Biological Chemistry</i> , 2001 , 276, 25813-22	5.4	53
119	Performance of BRCA1/2 mutation prediction models in Asian Americans. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4752-8	2.2	52
118	A kinase-independent function of c-Abl in promoting proteolytic destruction of damaged DNA binding proteins. <i>Molecular Cell</i> , 2006 , 22, 489-99	17.6	49
117	Genetic predisposition to gastric cancer. <i>Seminars in Oncology</i> , 2016 , 43, 554-559	5.5	47
116	Reduced global genomic repair of ultraviolet light-induced cyclobutane pyrimidine dimers in simian virus 40-transformed human cells. <i>Molecular Carcinogenesis</i> , 2000 , 29, 17-24	5	43
115	Linked read sequencing resolves complex genomic rearrangements in gastric cancer metastases. <i>Genome Medicine</i> , 2017 , 9, 57	14.4	42
114	Tumor Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance. <i>Clinical Cancer Research</i> , 2017 , 23, 3365-3370	12.9	39

113	Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 2851-2858	12.9	38
112	BRCA1 and p53: compensatory roles in DNA repair. <i>Journal of Molecular Medicine</i> , 2003 , 81, 700-7	5.5	37
111	American Gastroenterological Association Technical Review on the Diagnosis and Management of Lynch Syndrome. <i>Gastroenterology</i> , 2015 , 149, 783-813.e20	13.3	35
110	Parent decision-making around the genetic testing of children for germline TP53 mutations. <i>Cancer</i> , 2015 , 121, 286-93	6.4	35
109	Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study. <i>Clinical Cancer Research</i> , 2006 , 12, 3389-93	12.9	35
108	The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer. <i>Cancer Genetics</i> , 2015 , 208, 448-54	2.3	33
107	Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. <i>BMC Pharmacology</i> , 2011 , 11, 7		33
106	Discovery and functional characterization of a neomorphic PTEN mutation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 13976-81	11.5	31
105	The MLH1 c.-27C>A and c.85G>T variants are linked to dominantly inherited MLH1 epimutation and are borne on a European ancestral haplotype. <i>European Journal of Human Genetics</i> , 2014 , 22, 617-24	5.3	30
104	Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2009 , 193, 9-18		30
103	Molecular inversion probe analysis of gene copy alterations reveals distinct categories of colorectal carcinoma. <i>Cancer Research</i> , 2006 , 66, 7910-9	10.1	29
102	Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015 , 27, 23-33	2.4	28
101	Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs. <i>Oncotarget</i> , 2018 , 9, 12316-12322	3.3	25
100	PARP inhibitors in breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2010 , 8, 629-35	0.6	25
99	HAT1 Coordinates Histone Production and Acetylation via H4 Promoter Binding. <i>Molecular Cell</i> , 2019 , 75, 711-724.e5	17.6	24
98	Quantitative and Sensitive Detection of Cancer Genome Amplifications from Formalin Fixed Paraffin Embedded Tumors with Droplet Digital PCR. <i>Translational Medicine (Sunnyvale, Calif)</i> , 2012 , 2,		24
97	Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3006-3006	2.2	23
96	Detection of Germline Mutation in Hereditary Breast and/or Ovarian Cancers by Next-Generation Sequencing on a Four-Gene Panel. <i>Journal of Molecular Diagnostics</i> , 2016 , 18, 580-94	5.1	23

95	PARP Inhibitors for the Treatment and Prevention of Breast Cancer. <i>Current Breast Cancer Reports</i> , 2010 , 2, 190-197	0.8	22
94	Patient communication of cancer genetic test results in a diverse population. <i>Translational Behavioral Medicine</i> , 2018 , 8, 85-94	3.2	21
93	Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinum and irinotecan in colorectal cancer cells. <i>Cancer Letters</i> , 2014 , 343, 217-23	9.9	20
92	A novel de novo BRCA1 mutation in a Chinese woman with early onset breast cancer. <i>Familial Cancer</i> , 2011 , 10, 233-7	3	19
91	Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair. <i>Cancer Research</i> , 2014 , 74, 6205-15	10.1	18
90	Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort. <i>World Journal of Surgery</i> , 2012 , 36, 702-13	3.3	17
89	The role of the retinoblastoma/E2F1 tumor suppressor pathway in the lesion recognition step of nucleotide excision repair. <i>DNA Repair</i> , 2009 , 8, 795-802	4.3	17
88	Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. <i>Health Expectations</i> , 2005 , 8, 221-33	3.7	17
87	Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1000-1000	2.2	17
86	Predicting and preventing hereditary colorectal cancer. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 296, 1521-3	27.4	16
85	Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers. <i>Oncotarget</i> , 2017 , 8, 26344-26355	3.3	14
84	Metastatic lobular breast carcinoma mimicking primary signet ring adenocarcinoma in a patient with a suspected CDH1 mutation. <i>Journal of Clinical Oncology</i> , 2015 , 33, e19-21	2.2	13
83	Strategies For Clinical Implementation: Precision Oncology At Three Distinct Institutions. <i>Health Affairs</i> , 2018 , 37, 751-756	7	13
82	Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol. <i>DNA Repair</i> , 2012 , 11, 522-4	4.3	13
81	Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012 , 136, 931-3	4.4	13
80	Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations. <i>BMC Medical Genomics</i> , 2019 , 12, 84	3.7	12
79	From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. <i>Value in Health</i> , 2018 , 21, 1062-1068	3.3	12
78	Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. <i>Clinical Cancer Research</i> , 2020 , 26, 2704-2710	12.9	12

77	BRCA1: Beyond double-strand break repair. <i>DNA Repair</i> , 2015 , 32, 165-171	4.3	11
76	A Chimeric ATP-Linked Nucleotide Enables Luminescence Signaling of Damage Surveillance by MTH1, a Cancer Target. <i>Journal of the American Chemical Society</i> , 2016 , 138, 9005-8	16.4	11
75	Identification of a Functional In Vivo p53 Response Element in the Coding Sequence of the Xeroderma Pigmentosum Group C Gene. <i>Genes and Cancer</i> , 2012 , 3, 131-40	2.9	11
74	DNA Damage, Repair, and Diseases. <i>Journal of Biomedicine and Biotechnology</i> , 2002 , 2, 45		11
73	IDH2 Mutation in a Patient with Metastatic Colon Cancer. <i>New England Journal of Medicine</i> , 2017 , 376, 1991-2	59.2	10
72	A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature. <i>Cancer Genetics and Cytogenetics</i> , 2007 , 179, 89-92		10
71	DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications. <i>Cancer Treatment Reviews</i> , 2016 , 44, 1-9	14.4	10
70	Increased MTH1-specific 8-oxodGTPase activity is a hallmark of cancer in colon, lung and pancreatic tissue. <i>DNA Repair</i> , 2019 , 83, 102644	4.3	9
69	Is breast cancer a part of Lynch syndrome?. <i>Breast Cancer Research</i> , 2012 , 14, 110	8.3	8
68	A rare case of an aldosterone secreting metastatic adrenocortical carcinoma and papillary thyroid carcinoma in a 31-year-old male. <i>Rare Tumors</i> , 2011 , 3, e45	1.1	8
67	Identification of a novel p53 in-frame deletion in a Li-Fraumeni-like family. <i>Pediatric Blood and Cancer</i> , 2008 , 50, 914-6	3	8
66	Germline Testing for Patients With Mutations on Somatic Tumor Testing. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkz095	4.6	7
65	Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	7
64	Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT Basket Trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 320-320	2.2	7
63	Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients. <i>Cancer</i> , 2021 , 127, 1275-1285	6.4	7
62	Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients: Clinical Testing with a Multigene Test Panel. <i>Journal of Molecular Diagnostics</i> , 2020 , 22, 544-554 ^{5.1}		6
61	Abstract CT138: NCI-MATCH EAY131 -Z11: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing BRCA1 and BRCA2 mutations 2019 ,		6
60	Rapid detection of recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels. <i>Oncotarget</i> , 2018 , 9, 7832-7843	3.3	6

59	High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2019 , 25, 5301-5314	12.9	5
58	JAVELIN BRCA/ATM: A phase 2 trial of avelumab (antiPD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS2660-TPS2660	2.2	5
57	Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst. <i>Journal of Physical Education and Sports Management</i> , 2018 , 4,	2.8	5
56	Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer. <i>Cancer Medicine</i> , 2021 , 10, 1012-1017	4.8	5
55	Precision medicine to improve survival without increasing costs in advanced cancer patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e17641-e17641	2.2	4
54	Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkaa054	4.6	4
53	DNA Damage Response Pathways and Cancer 2020 , 154-164.e4		4
52	Genomics in medicine: a novel elective rotation for internal medicine residents. <i>Postgraduate Medical Journal</i> , 2019 , 95, 569-572	2	3
51	Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2-Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine. <i>JCO Precision Oncology</i> , 2017 , 1,	3.6	3
50	Abstract P5-04-03: Deconvoluting immune cell populations using <i>In silico</i> flow cytometry with CIBERSORT: Association with neoadjuvant therapy response and genomic instability in TNBC 2015 ,		3
49	Prevalence and molecular etiology of mismatch repair deficiency among gastrointestinal cancers.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 215-215	2.2	3
48	DNA Damage Response Pathways and Cancer 2008 , 139-152		3
47	A novel DDB2 mutation causes defective recognition of UV-induced DNA damages and prevalent equine squamous cell carcinoma. <i>DNA Repair</i> , 2021 , 97, 103022	4.3	3
46	A young woman with bilateral breast cancer: identifying a genetic cause and implications for management. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 512-7	7.3	2
45	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	2
44	A phase II clinical trial of talazoparib monotherapy for PALB2 mutation-associated advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS1109-TPS1109	2.2	2
43	Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational Study.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-12	3.6	2
42	Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?. <i>JCO Precision Oncology</i> , 2018 , 2, 1-10	3.6	2

41	MITI minimum information guidelines for highly multiplexed tissue images.. <i>Nature Methods</i> , 2022 , 19, 262-267	21.6	2
40	Whole genome analysis identifies the association of TP53 genomic deletions with lower survival in Stage III colorectal cancer. <i>Scientific Reports</i> , 2020 , 10, 5009	4.9	1
39	Chromatin Remodeling in Response to BRCA2-Crisis. <i>Cell Reports</i> , 2019 , 28, 2182-2193.e6	10.6	1
38	Multiple-Gene Panels and the Future of Genetic Testing. <i>Current Breast Cancer Reports</i> , 2015 , 7, 98-104	0.8	1
37	Genetic Polymorphisms as Predictors of Breast Cancer Risk. <i>Current Breast Cancer Reports</i> , 2012 , 4, 232-239		1
36	Surgery for Hereditary Diffuse Gastric Cancer: Long-Term Outcomes.. <i>Cancers</i> , 2022 , 14,	6.6	1
35	Phase II Study of Taselisib in -Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100424	3.6	1
34	A quality outcomes analysis following treatment with personalized genomic cancer medicine.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 12-12	2.2	1
33	A phase II study of capecitabine, carboplatin, and bevacizumab for metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 115-115	2.2	1
32	Combined Homologous Recombination Deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple-negative and/or BRCA1/2 mutation-associated breast cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1018-1018	2.2	1
31	Clinical impact of multi-gene panel testing for hereditary breast and ovarian cancer risk assessment.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1513-1513	2.2	1
30	Pathogenic germline mutations in emerging cancer genes: What happens after panel testing?. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1528-1528	2.2	1
29	Preventive surgery after multiplex genetic panel testing (MGPT).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1525-1525	2.2	1
28	Implementation of a precision cancer program in an integrated health care system.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e17647-e17647	2.2	1
27	DNA Damage Response Pathways and Cancer 2014 , 142-153.e3		1
26	Single-cell analyses reveal a continuum of cell state and composition changes in the malignant transformation of polyps to colorectal cancer		1
25	Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial. <i>Cancers</i> , 2022 , 14, 2716	6.6	1
24	BRCA1: a movement toward cancer prevention. <i>Molecular and Cellular Oncology</i> , 2015 , 2, e979685	1.2	0

23	Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. <i>Journal of Clinical and Translational Hepatology</i> , 2020 , 8, 377-384	5.2	0
22	Tumor Molecular Profiling Aids in Determining Tissue of Origin and Therapy for Metastatic Adenocarcinoma in a Patient With Multiple Primary Malignancies.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-4	3.6	0
21	Somatic tumor testing implications for Lynch syndrome germline genetic testing.. <i>Cancer Genetics</i> , 2022 , 264-265, 16-22	2.3	0
20	Lupus antibody tops cancer cells. <i>Science Translational Medicine</i> , 2012 , 4, 157fs38	17.5	
19	Identifying and Preventing High-risk Gastric Cancer Individuals With CDH1 Mutations. <i>Annals of Surgery</i> , 2008 , 247, 715-716	7.8	
18	Gastric Cancer Registry: A comprehensive patient-reported resource for multidisciplinary and translational genomic approaches to gastric cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 432-432	2.2	
17	Molecular Inversion Probes (MIPs) Identify Novel Areas of Allelic Imbalance in Childhood Leukemia.. <i>Blood</i> , 2007 , 110, 1438-1438	2.2	
16	Promoting colorectal cancer (CRC) screening after multiplex genetic testing and genetic counseling.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1582-1582	2.2	
15	Promoting breast cancer screening after multiplex genetic panel testing (MGPT) and genetic counseling.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1581-1581	2.2	
14	Clinicopathologic features of invasive breast cancer (BC) diagnosed in carriers of germline PALB2, CHEK2 and ATM pathogenic variants.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1549-1549	2.2	
13	Pretreatment lab values to predict overall survival in patients with primary unresectable pancreatic adenocarcinoma treated with SBRT.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 433-433	2.2	
12	Design and implementation of an informatics infrastructure for actionable precision oncology.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e17521-e17521	2.2	
11	Association of tumor BRCA1 reversion mutation arising during neoadjuvant platinum-based therapy in breast cancer (BC) with therapy resistance.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1094-1094	2.2	
10	Molecular profiling (MP) programs to increase access to targeted therapies in a rural setting.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e17576-e17576	2.2	
9	Optimizing Genotype Matched Clinical Trial (GMCT) accrual in a community oncology program (COP).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e18036-e18036	2.2	
8	Higher peripheral lymphocyte count to predict survival in triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1010-1010	2.2	
7	Yield of multiplex panel testing compared to expert opinion and validated prediction models.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1509-1509	2.2	
6	Genomic profiling and targeted therapy in cholangiocarcinoma to yield positive clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e23162-e23162	2.2	

- 5 Expanded yield of multiplex panel testing in fully accrued prospective trial.. *Journal of Clinical Oncology*, **2017**, 35, 1525-1525 2.2
- 4 Performance of mutation risk prediction models in a racially diverse multi-gene panel testing cohort.. *Journal of Clinical Oncology*, **2017**, 35, 1523-1523 2.2
- 3 Safety of multiplex gene testing for inherited cancer risk in a fully accrued prospective trial.. *Journal of Clinical Oncology*, **2017**, 35, 1576-1576 2.2
- 2 Seventh edition (2010) of gastric adenocarcinoma AJCC staging system: Is there room for improvement?. *Journal of Clinical Oncology*, **2012**, 30, 77-77 2.2
- 1 Subtle endoscopic manifestations of diffuse signet cell gastric adenocarcinoma in patients with CDH1 mutations. *Gastrointestinal Endoscopy*, **2021**, 94, 1146-1147 5.2